Peptic Ulcer Drugs Market size was USD 4.48 Billion in 2023 and is expected to reach USD 5.59 Billion by 2031 and grow at a CAGR of 2.80% over the forecast period of 2024-2031.
The peptic ulcer drugs market refers to the pharmaceutical industry segment dedicated to the development, manufacturing, and sale of medications used in the treatment of peptic ulcers. Peptic ulcers are open sores that can develop on the lining of the stomach, small intestine, or oesophagus, and they are often caused by the erosion of the protective mucous layer in these areas due to the presence of stomach acid. The peptic ulcer drugs market includes a range of medications that help manage and heal peptic ulcers by reducing stomach acid production, protecting the lining of the digestive tract, or eradicating the bacteria Helicobacter pylori, which is associated with the development of many peptic ulcers. Proton pump inhibitors are drugs that inhibit the enzyme responsible for acid production in the stomach, reducing acid levels and promoting ulcer healing.
Get More Information on Peptic Ulcer Drugs Market - Request Sample Report
One of the major drivers driving market expansion is the rising frequency of peptic ulcers, particularly among the elderly. Furthermore, bad living choices and an increase in stomach cancer cases are leading to an increase in the number of people suffering from peptic ulcers. This, combined with the evolving customer preference for different peptic ulcer-curing medications over invasive operations, is contributing to market expansion. In keeping with this, as compared to surgical methods, certain steroidal anti-inflammatory drugs are less intrusive, less expensive, and allow for speedier recovery while minimizing blood loss.H2-receptor blockers also reduce stomach acid production but act through a different mechanism compared to PPIs. Antacids are fast-acting drugs that neutralize stomach acid, providing short-term relief from ulcer-related symptoms. Antibiotics are When Helicobacter pylori infection is present, antibiotics may be prescribed in combination with other ulcer medications to eradicate the bacteria. Cytoprotective agents are drugs that help protect the lining of the stomach and intestines, promoting healing and preventing further damage. The peptic ulcer drugs market is influenced by factors such as the prevalence of peptic ulcers, the adoption of advanced treatment options, research and development activities for new drugs, and the regulatory environment in different regions.
DRIVERS:
The incidence of peptic ulcers remains significant globally. Factors such as unhealthy dietary habits, stress, smoking, excessive alcohol consumption, and infection with Helicobacter pylori bacterium contribute to the development of peptic ulcers.
Increasing Geriatric Population are the biggest driver of this market.
Peptic ulcers are more prevalent among older adults. As the global population ages, the number of people at higher risk of developing peptic ulcers also increases, leading to a greater need for effective drugs for treatment and management.
RESTRAIN:
Many peptic ulcer treatments have been on the market for a long time, and their parents may have expired, allowing generic drug makers to create and sell less expensive copies of these medications.
Safety and Side Effects Concerns are the primary impediments in this sector.
Some peptic ulcer drugs, especially long-term use of certain medications like proton pump inhibitors (PPIs), have been associated with potential side effects. These may include increased risks of kidney disease, fractures, and nutrient deficiencies. Safety concerns can lead to reduced patient adherence to treatment and hesitancy among healthcare providers to prescribe certain drugs.
OPPORTUNITY:
As economies expand and healthcare costs rise, there is a potential for increased healthcare investment, including the procurement of sophisticated and new peptic ulcer medications.
Biotechnology advancements represent a significant possibility in this sector.
Advances in biotechnology and drug delivery systems can lead to the development of novel formulations and drug delivery methods, potentially improving the efficacy and safety of peptic ulcer drugs.
CHALLENGES:
Helicobacter pylori, a common cause of peptic ulcers, can develop resistance to antibiotics used for treatment.
The key obstacles of this industry include side effects and safety concerns.
Some peptic ulcer drugs, such as proton pump inhibitors (PPIs) and long-term use of certain medications, have been associated with potential side effects, including kidney problems, fractures, and nutrient deficiencies. Managing these side effects and ensuring patient safety are ongoing challenges.
Asia shipped more than $2.01 billion in pharmaceutical items to Ukraine in FY21, an almost 52% decrease was observed over the period of 2022. while Russia contributed nearly $6.2 Billion last fiscal year, representing a 7.21 % increase over the previous year. Pharmaceuticals are facing the brunt of the damage. Russia and Ukraine are significant pharmaceutical export markets. Some Asian pharmaceutical businesses have a significant presence in these markets. The current Russian-Ukrainian war has had a huge impact on the Indian pharmaceutical business.
Asia is Ukraine's third-largest pharmaceutical exporter, and the conflict has affected global commerce, leading to higher manufacturing and shipping costs, inflation, and trade payment concerns. A lot of raw material goes from Russia to the whole world for pharmaceuticals, but due to this war, there has been an increase in the raw material and its supply chain, there is also a 6-7% increase in the prices of peptic ulcer drugs.
IMPACT OF ONGOING RECESSION
Pharma has traditionally been seen as one of the few recession-proof businesses, bowing less under economic downturns and stress than others. However, according to a recent poll, it is not immune to macroeconomic challenges. According to a recent Global Data poll, the top problem for the pharmaceutical business in 2022-23 is inflation, followed by medication price and reimbursement. Pharma's yearly prescription price increases, which occur in January, have seen a 4-6% increase in list prices so far this year, remaining below the national consumer inflation rate of roughly 7-9% in 2022.
That medicine price increase is slightly smaller than in prior years, indicating that the pharmaceutical sector isn't yet attempting to adjust for a new Inflation Reduction Act rule that went into effect on January 1. All the databases peptic ulcer drugs market are increasing their prices.
By Drugs Type
Antibiotics
H2 Antagonists
Proton Pump Inhibitor
Others
By Ulcer Type
Duodenal Ulcer
Gastric Ulcer
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
North America: North America has the market's highest revenue share. The high frequency of peptic ulcers, a big older population base, and improved healthcare infrastructure can all be related to segment expansion. North America's market is rising as a result of high healthcare spending, quick development in R&D activities, and technological advancement. A large number of market participants and a rise in unique product approvals are also expected to enhance the sector.
Asia Pacific: The Asia Pacific market is predicted to develop at a quicker rate due to improved healthcare infrastructure, more population awareness, and the increasing prevalence of peptic ulcer disease. Latin America, the Middle East, and Africa are expected to increase at a slower rate due to unmet healthcare requirements, poor awareness, and a growing healthcare industry.
Some major key players in Peptic Ulcer Drugs Market are AstraZeneca plc, Abbott Laboratories, Novitium Pharma LLC, Boehringer Ingelheim International GmbH, PharmaKing Co. Ltd., Pfizer Inc., Yuhan Corporation, RedHill Biopharma Ltd, Zydus Lifesciences Limited, etc., Viatris Inc., and other players.
In 2021: Famotidine, a common treatment for stomach ulcers, is being studied as a potential cure for the coronavirus at Northwell Health in New York City.
In 2021: The FDA approved RHB-105, a three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule that successfully eradicates Helicobacter pylori infection in adults, developed by researchers at the Michael E. De-Bakey Veterans Affairs Medical Centre.
| Report Attributes | Details |
| Market Size in 2022 | US$ 4.36 Bn |
| Market Size by 2030 | US$ 5.35 Bn |
| CAGR | CAGR of 2.6 % From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drugs Type (Antibiotics, H2 Antagonists, Proton Pump Inhibitor, Others) • By Ulcer Type (Duodenal Ulcer and Gastric Ulcer) • By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | AstraZeneca plc, Abbott Laboratories, Novitium Pharma LLC, Boehringer Ingelheim International GmbH, PharmaKing Co. Ltd., Pfizer Inc., Yuhan Corporation, RedHill Biopharma Ltd, Zydus Lifesciences Limited, etc., Viatris Inc. |
| Key Drivers | • The incidence of peptic ulcers remains significant globally. Factors such as unhealthy dietary habits, stress, smoking, excessive alcohol consumption, and infection with Helicobacter pylori bacterium contribute to the development of peptic ulcers. • Increasing Geriatric Population are the biggest driver of this market. |
| Market Restraints | • Many peptic ulcer treatments have been on the market for a long time, and their parents may have expired, allowing generic drug makers to create and sell less expensive copies of these medications. • Safety and Side Effects Concerns are the primary impediments in this sector. |
Ans. Over the projection period, the compound annual growth rate for the Peptic Ulcer Drugs Market is 2.6%.
Ans. By 2030, the market for Peptic Ulcer Drugs is expected to be worth USD 5.35 Billion.
Ans. The largest geographic market for peptic ulcer medications is North America, followed by Europe and Asia-Pacific.
Ans. In 2022, the Proton pump inhibitors (Ps) category dominated the market.
Ans. The Duodenal Ulcer has the biggest market share.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Peptic Ulcer Drugs Market Segmentation, By Drugs Type
8.1 Antibiotics
8.2 H2 Antagonists
8.3 Proton Pump Inhibitors
8.4 Others
9. Peptic Ulcer Drugs Market Segmentation, By Ulcer Type
9.1 Duodenal Ulcer
9.2 Gastric Ulcer
10. Peptic Ulcer Drugs Market Segmentation, By Distribution Channel
10.1 Retail Pharmacies
10.2 Hospital Pharmacies
10.3 Online Pharmacies
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Peptic Ulcer Drugs Market by Country
11.2.2 North America Peptic Ulcer Drugs Market by Drugs Class
11.2.3 North America Peptic Ulcer Drugs Market by Ulcer Type
11.2.4 North America Peptic Ulcer Drugs Market by Distribution Channel
11.2.5 USA
11.2.5.1 USA Peptic Ulcer Drugs Market by Drugs Class
11.2.5.2 USA Peptic Ulcer Drugs Market by Ulcer Type
11.2.5.3 USA Peptic Ulcer Drugs Market by Distribution Channel
11.2.6 Canada
11.2.6.1 Canada Peptic Ulcer Drugs Market by Drugs Class
11.2.6.2 Canada Peptic Ulcer Drugs Market by Ulcer Type
11.2.6.3 Canada Peptic Ulcer Drugs Market by Distribution Channel
11.2.7 Mexico
11.2.7.1 Mexico Peptic Ulcer Drugs Market by Drugs Class
11.2.7.2 Mexico Peptic Ulcer Drugs Market by Ulcer Type
11.2.7.3 Mexico Peptic Ulcer Drugs Market by Distribution Channel
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Peptic Ulcer Drugs Market by Country
11.3.1.2 Eastern Europe Peptic Ulcer Drugs Market by Drugs Class
11.3.1.3 Eastern Europe Peptic Ulcer Drugs Market by Ulcer Type
11.3.1.4 Eastern Europe Peptic Ulcer Drugs Market by Distribution Channel
11.3.1.5 Poland
11.3.1.5.1 Poland Peptic Ulcer Drugs Market by Drugs Class
11.3.1.5.2 Poland Peptic Ulcer Drugs Market by Ulcer Type
11.3.1.5.3 Poland Peptic Ulcer Drugs Market by Distribution Channel
11.3.1.6 Romania
11.3.1.6.1 Romania Peptic Ulcer Drugs Market by Drugs Class
11.3.1.6.2 Romania Peptic Ulcer Drugs Market by Ulcer Type
11.3.1.6.4 Romania Peptic Ulcer Drugs Market by Distribution Channel
11.3.1.7 Turkey
11.3.1.7.1 Turkey Peptic Ulcer Drugs Market by Drugs Class
11.3.1.7.2 Turkey Peptic Ulcer Drugs Market by Ulcer Type
11.3.1.7.3 Turkey Peptic Ulcer Drugs Market by Distribution Channel
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Peptic Ulcer Drugs Market by Drugs Class
11.3.1.8.2 Rest of Eastern Europe Peptic Ulcer Drugs Market by Ulcer Type
11.3.1.8.3 Rest of Eastern Europe Peptic Ulcer Drugs Market by Distribution Channel
11.3.2 Western Europe
11.3.2.1 Western Europe Peptic Ulcer Drugs Market by Country
11.3.2.2 Western Europe Peptic Ulcer Drugs Market by Drugs Class
11.3.2.3 Western Europe Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.4 Western Europe Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.5 Germany
11.3.2.5.1 Germany Peptic Ulcer Drugs Market by Drugs Class
11.3.2.5.2 Germany Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.5.3 Germany Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.6 France
11.3.2.6.1 France Peptic Ulcer Drugs Market by Drugs Class
11.3.2.6.2 France Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.6.3 France Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.7 UK
11.3.2.7.1 UK Peptic Ulcer Drugs Market by Drugs Class
11.3.2.7.2 UK Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.7.3 UK Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.8 Italy
11.3.2.8.1 Italy Peptic Ulcer Drugs Market by Drugs Class
11.3.2.8.2 Italy Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.8.3 Italy Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.9 Spain
11.3.2.9.1 Spain Peptic Ulcer Drugs Market by Drugs Class
11.3.2.9.2 Spain Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.9.3 Spain Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.10 Netherlands
11.3.2.10.1 Netherlands Peptic Ulcer Drugs Market by Drugs Class
11.3.2.10.2 Netherlands Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.10.3 Netherlands Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.11 Switzerland
11.3.2.11.1 Switzerland Peptic Ulcer Drugs Market by Drugs Class
11.3.2.11.2 Switzerland Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.11.3 Switzerland Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.1.12 Austria
11.3.2.12.1 Austria Peptic Ulcer Drugs Market by Drugs Class
11.3.2.12.2 Austria Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.12.3 Austria Peptic Ulcer Drugs Market by Distribution Channel
11.3.2.13 Rest of Western Europe
11.3.2.13.1 Rest of Western Europe Peptic Ulcer Drugs Market by Drugs Class
11.3.2.13.2 Rest of Western Europe Peptic Ulcer Drugs Market by Ulcer Type
11.3.2.13.3 Rest of Western Europe Peptic Ulcer Drugs Market by Distribution Channel
11.4 Asia-Pacific
11.4.1 Asia-Pacific Peptic Ulcer Drugs Market by Country
11.4.2 Asia-Pacific Peptic Ulcer Drugs Market by Drugs Class
11.4.3 Asia-Pacific Peptic Ulcer Drugs Market by Ulcer Type
11.4.4 Asia-Pacific Peptic Ulcer Drugs Market by Distribution Channel
11.4.5 China
11.4.5.1 China Peptic Ulcer Drugs Market by Drugs Class
11.4.5.2 China Peptic Ulcer Drugs Market by Ulcer Type
11.4.5.3 China Peptic Ulcer Drugs Market by Distribution Channel
11.4.6 India
11.4.6.1 India Peptic Ulcer Drugs Market by Drugs Class
11.4.6.2 India Peptic Ulcer Drugs Market by Ulcer Type
11.4.6.3 India Peptic Ulcer Drugs Market by Distribution Channel
11.4.7 japan
11.4.7.1 Japan Peptic Ulcer Drugs Market by Drugs Class
11.4.7.2 Japan Peptic Ulcer Drugs Market by Ulcer Type
11.4.7.3 Japan Peptic Ulcer Drugs Market by Distribution Channel
11.4.8 South Korea
11.4.8.1 South Korea Peptic Ulcer Drugs Market by Drugs Class
11.4.8.2 South Korea Peptic Ulcer Drugs Market by Ulcer Type
11.4.8.3 South Korea Peptic Ulcer Drugs Market by Distribution Channel
11.4.9 Vietnam
11.4.9.1 Vietnam Peptic Ulcer Drugs Market by Drugs Class
11.4.9.2 Vietnam Peptic Ulcer Drugs Market by Ulcer Type
11.4.9.3 Vietnam Peptic Ulcer Drugs Market by Distribution Channel
11.4.10 Singapore
11.4.10.1 Singapore Peptic Ulcer Drugs Market by Drugs Class
11.4.10.2 Singapore Peptic Ulcer Drugs Market by Ulcer Type
11.4.10.3 Singapore Peptic Ulcer Drugs Market by Distribution Channel
11.4.11 Australia
11.4.11.1 Australia Peptic Ulcer Drugs Market by Drugs Class
11.4.11.2 Australia Peptic Ulcer Drugs Market by Ulcer Type
11.4.11.3 Australia Peptic Ulcer Drugs Market by Distribution Channel
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Peptic Ulcer Drugs Market by Drugs Class
11.4.12.2 Rest of Asia-Pacific Peptic Ulcer Drugs Market by Ulcer Type
11.4.12.3 Rest of Asia-Pacific Peptic Ulcer Drugs Market by Distribution Channel
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Peptic Ulcer Drugs Market by Country
11.5.1.2 Middle East Peptic Ulcer Drugs Market by Drugs Class
11.5.1.3 Middle East Peptic Ulcer Drugs Market by Ulcer Type
11.5.1.4 Middle East Peptic Ulcer Drugs Market by Distribution Channel
11.5.1.5 UAE
11.5.1.5.1 UAE Peptic Ulcer Drugs Market by Drugs Class
11.5.1.5.2 UAE Peptic Ulcer Drugs Market by Ulcer Type
11.5.1.5.3 UAE Peptic Ulcer Drugs Market by Distribution Channel
11.5.1.6 Egypt
11.5.1.6.1 Egypt Peptic Ulcer Drugs Market by Drugs Class
11.5.1.6.2 Egypt Peptic Ulcer Drugs Market by Ulcer Type
11.5.1.6.3 Egypt Peptic Ulcer Drugs Market by Distribution Channel
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Peptic Ulcer Drugs Market by Drugs Class
11.5.1.7.2 Saudi Arabia Peptic Ulcer Drugs Market by Ulcer Type
11.5.1.7.3 Saudi Arabia Peptic Ulcer Drugs Market by Distribution Channel
11.5.1.8 Qatar
11.5.1.8.1 Qatar Peptic Ulcer Drugs Market by Drugs Class
11.5.1.8.2 Qatar Peptic Ulcer Drugs Market by Ulcer Type
11.5.1.8.3 Qatar Peptic Ulcer Drugs Market by Distribution Channel
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Peptic Ulcer Drugs Market by Drugs Class
11.5.1.9.2 Rest of Middle East Peptic Ulcer Drugs Market by Ulcer Type
11.5.1.9.3 Rest of Middle East Peptic Ulcer Drugs Market by Distribution Channel
11.5.2 Africa
11.5.2.1 Africa Peptic Ulcer Drugs Market by Country
11.5.2.2 Africa Peptic Ulcer Drugs Market by Drugs Class
11.5.2.3 Africa Peptic Ulcer Drugs Market by Ulcer Type
11.5.2.4 Africa Peptic Ulcer Drugs Market by Distribution Channel
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Peptic Ulcer Drugs Market by Drugs Class
11.5.2.5.2 Nigeria Peptic Ulcer Drugs Market by Ulcer Type
11.5.2.5.3 Nigeria Peptic Ulcer Drugs Market by Distribution Channel
11.5.2.6 South Africa
11.5.2.6.1 South Africa Peptic Ulcer Drugs Market by Drugs Class
11.5.2.6.2 South Africa Peptic Ulcer Drugs Market by Ulcer Type
11.5.2.6.3 South Africa Peptic Ulcer Drugs Market by Distribution Channel
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Peptic Ulcer Drugs Market by Drugs Class
11.5.2.7.2 Rest of Africa Peptic Ulcer Drugs Market by Ulcer Type
11.5.2.7.3 Rest of Africa Peptic Ulcer Drugs Market by Distribution Channel
11.6 Latin America
11.6.1 Latin America Peptic Ulcer Drugs Market by Country
11.6.2 Latin America Peptic Ulcer Drugs Market by Drugs Class
11.6.3 Latin America Peptic Ulcer Drugs Market by Ulcer Type
11.6.4 Latin America Peptic Ulcer Drugs Market by Distribution Channel
11.6.5 Brazil
11.6.5.1 Brazil America Peptic Ulcer Drugs Market by Drugs Class
11.6.5.2 Brazil America Peptic Ulcer Drugs Market by Ulcer Type
11.6.5.3 Brazil America Peptic Ulcer Drugs Market by Distribution Channel
11.6.6 Argentina
11.6.6.1 Argentina America Peptic Ulcer Drugs Market by Drugs Class
11.6.6.2 Argentina America Peptic Ulcer Drugs Market by Ulcer Type
11.6.6.3 Argentina America Peptic Ulcer Drugs Market by Distribution Channel
11.6.7 Colombia
11.6.7.1 Colombia America Peptic Ulcer Drugs Market by Drugs Class
11.6.7.2 Colombia America Peptic Ulcer Drugs Market by Ulcer Type
11.6.7.3 Colombia America Peptic Ulcer Drugs Market by Distribution Channel
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Peptic Ulcer Drugs Market by Drugs Class
11.6.8.2 Rest of Latin America Peptic Ulcer Drugs Market by Ulcer Type
11.6.8.3 Rest of Latin America Peptic Ulcer Drugs Market by Distribution Channel
12 Company profile
12.1 AstraZeneca plc
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Novitium Pharma LLC
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Boehringer Ingelheim International GmbH
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 PharmaKing Co. Ltd.
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Pfizer Inc.
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Yuhan Corporation
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 RedHill Biopharma Ltd
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Zydus Lifesciences Limited
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Viatris Inc.
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The mRNA Therapeutics Market size was valued at USD 40.06 billion in 2023 and is expected to grow at USD 45.85 billion by 2031, and grow at a CAGR of 1.7 % over the forecast period of 2024-2031.
The Patient Portal Market Size was valued at USD 3.45 billion in 2022, and is expected to reach USD 14.36 billion by 2030, and grow at a CAGR of 19.5% over the forecast period 2023-2030.
The Health IT Security Market Size was valued at USD 12.35 billion in 2022, and is expected to reach USD 19.10 billion by 2030, and grow at a CAGR of 15.6% over the forecast period 2023-2030.
The Canada Medical Isotope market size for Canada was valued at USD 911.17 million in 2022 and is expected to reach USD 2223.99 million in 2031 and grow at a CAGR of 11.8% over the forecast period of 2024-2031.
Tuberculosis (TB) Diagnostics Market size was valued at USD 2.16 billion in 2023 and is expected to reach USD 3.60 billion By 2031 and grow at a CAGR of 6.60% over the forecast period of 2024-2031.
The size was valued at USD 448.25 Million in 2022 and is expected to reach USD 618.20 Million By 2030 and grow at a CAGR of 4.1% over the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
